Trials / Unknown
UnknownNCT05035953
Thrombolysis Combined With Edaravone Dexborneol on Hemorrhagic Transformation for Acute Ischemic Stroke
Effect of Thrombolysis Combined With Edaravone Dexborneol for Acute Ischemic Stroke Patients: a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- Sponsor
- Huashan Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
To explore the safety and efficacy of edaravone dexborneol for the treatment of acute ischemic stroke patients who received thrombolysis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Edaravone Dexborneol | Edaravone Dexborneol 37.5 mg (containing Edaravone 30 mg and Dexborneol 7.5 mg), BID, 14 days, addition to thrombolysis |
| DRUG | Placebo | Edaravone Dexborneol matching injection, addition to thrombolysis |
Timeline
- Start date
- 2021-09-13
- Primary completion
- 2023-09-13
- Completion
- 2024-03-13
- First posted
- 2021-09-05
- Last updated
- 2021-09-05
Source: ClinicalTrials.gov record NCT05035953. Inclusion in this directory is not an endorsement.